Biodesix awarded US patent for VeriStrat serum test

NewsGuard 100/100 Score

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy. Drug therapies directed against the epidermal growth factor pathway and related molecular targets play an increasingly important role in cancer therapy and represent the majority of oncology therapies in development, but do not provide benefit for all patients.

“The granting of this patent recognizes our unique approach and innovation in this exciting area of molecular diagnostics”

The patent also covers mass-spectrometry processes, algorithms and other important aspects of the Company's core technology, ProTS®, and represents the cornerstone of the Company's growing intellectual property portfolio.

"The granting of this patent recognizes our unique approach and innovation in this exciting area of molecular diagnostics," commented David Brunel, Biodesix CEO. "We are committed to applying our technology to develop clinically meaningful tests that enhance clinical decision making and patient care."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative breast cancer treatment sequence yields positive results